Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?

by Simone U. Dalm, Marion de Jong
Published 2017-09-01

Review: Receptor Targeted Nuclear Imaging of Breast Cancer

by Simone U. Dalm, John Fred Verzijlbergen, Marion De Jong
Published 2017-01-01

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research

by Eline A.M. Ruigrok, Wytske M. van Weerden, Julie Nonnekens, Marion de Jong
Published 2019-10-01

Segmentation and visual analysis of whole-body mouse skeleton microSPECT.

by Artem Khmelinskii, Harald C Groen, Martin Baiker, Marion de Jong, Boudewijn P F Lelieveldt
Published 2012-01-01

Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands

by Panagiotis Kanellopoulos, Aikaterini Kaloudi, Marion de Jong, Eric P. Krenning, Berthold A. Nock, Theodosia Maina
Published 2020-06-01

Multimodality Imaging of Somatostatin Receptor–Positive Tumors with Nuclear and Bioluminescence Imaging

by Stefan E. Pool, Timo L.M. ten Hagen, Stuart Koelewijn, Marion de Jong, Gerben A. Koning
Published 2012-01-01

[^99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models

by Panagiotis Kanellopoulos, Emmanouil Lymperis, Aikaterini Kaloudi, Marion de Jong, Eric P. Krenning, Berthold A. Nock, Theodosia Maina
Published 2020-07-01

Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair

by Emmanouil Lymperis, Aikaterini Kaloudi, Panagiotis Kanellopoulos, Marion de Jong, Eric P. Krenning, Berthold A. Nock, Theodosia Maina
Published 2019-03-01

In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.

by Ho Sze Chan, Erik de Blois, Alfred Morgenstern, Frank Bruchertseifer, Marion de Jong, Wouter Breeman, Mark Konijnenberg
Published 2017-01-01

Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy

by Sofia Koustoulidou, Mark W. H. Hoorens, Simone U. Dalm, Shweta Mahajan, Reno Debets, Yann Seimbille, Marion de Jong
Published 2021-03-01

One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [^99mTc]Tc-DB4 and [¹¹¹In]In-SG4 in Mice Treated with Entresto

by Panagiotis Kanellopoulos, Aikaterini Kaloudi, Maritina Rouchota, George Loudos, Marion de Jong, Eric P. Krenning, Berthold A. Nock, Theodosia Maina
Published 2020-11-01

Can DCE-MRI explain the heterogeneity in radiopeptide uptake imaged by SPECT in a pancreatic neuroendocrine tumor model?

by Karin Bol, Joost C Haeck, Harald C Groen, Wiro J Niessen, Monique R Bernsen, Marion de Jong, Jifke F Veenland
Published 2013-01-01

Localization of ^99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses

by Aikaterini Kaloudi, Emmanouil Lymperis, Panagiotis Kanellopoulos, Beatrice Waser, Marion de Jong, Eric P. Krenning, Jean Claude Reubi, Berthold A. Nock, Theodosia Maina
Published 2019-03-01

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice

by Aikaterini Kaloudi, Emmanouil Lymperis, Athina Giarika, Simone Dalm, Francesca Orlandi, Donato Barbato, Mattia Tedesco, Theodosia Maina, Marion de Jong, Berthold A. Nock
Published 2017-11-01

Generation of fluorescently labeled tracers – which features influence the translational potential?

by Fijs W. B. van Leeuwen, Bart Cornelissen, Federico Caobelli, Laura Evangelista, Latifa Rbah-Vidal, Silvana Del Vecchio, Catarina Xavier, Jacques Barbet, Marion de Jong
Published 2017-12-01

Facilitating tumor functional assessment by spatially relating 3D tumor histology and in vivo MRI: image registration approach.

by Lejla Alic, Joost C Haeck, Karin Bol, Stefan Klein, Sandra T van Tiel, Piotr A Wielepolski, Marion de Jong, Wiro J Niessen, Monique Bernsen, Jifke F Veenland
Published 2011-01-01

Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy

by Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong, Wouter A. P. Breeman
Published 2016-05-01

Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity

by Giulia Tamborino, Marijke De Saint-Hubert, Lara Struelens, Dayana C. Seoane, Eline A. M. Ruigrok, An Aerts, Wiggert A. van Cappellen, Marion de Jong, Mark W. Konijnenberg, Julie Nonnekens
Published 2020-02-01

Folate Receptor–Targeted Single-Photon Emission Computed Tomography/Computed Tomography to Detect Activated Macrophages in Atherosclerosis: Can It Distinguish Vulnerable from Stabl...

by Leah C.J. Winkel, Harald C. Groen, Bibi S. van Thiel, Cristina Müller, Antonius F.W. van der Steen, Jolanda J. Wentzel, Marion de Jong, Kim Van der Heiden
Published 2014-01-01

Perspectives on Small Animal Radionuclide Imaging; Considerations and Advances in Atherosclerosis

by Eric J. Meester, Eric J. Meester, B. J. Krenning, J. de Swart, M. Segbers, H. E. Barrett, H. E. Barrett, M. R. Bernsen, K. Van der Heiden, Marion de Jong
Published 2019-03-01